Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | NOX1 | Q9Y5S8 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9813210 | 0.88 | MAPT (0.41) | SNCAMAPTKMT2AMEN1NOX1 | |
| SCHEMBL9813116 | 0.87 | NOX1 (0.41) | SNCAMAPTKMT2AMEN1NOX1 | |
| SCHEMBL10569969 | 0.86 | SNCA (0.50) | SNCAMAPTKMT2AMEN1NOX1 | |
| SCHEMBL10575740 | 0.83 | MEN1 (0.45) | SNCAMAPTKMT2AMEN1NOX1 | |
| SCHEMBL10592334 | 0.80 | SNCA (0.41) | SNCAMAPTKMT2AMEN1NOX1 | |
| SCHEMBL10590992 | 0.77 | MAPT (0.44) | SNCAMAPTKMT2AMEN1NOX1 | |
| SCHEMBL9813228 | 0.73 | SNCA (0.52) | SNCAMAPTKMT2AMEN1NOX1 | |
| SCHEMBL10592294 | 0.73 | MAPT (0.51) | SNCAMAPTKMT2AMEN1NOX1 | |
| SCHEMBL10590546 | 0.71 | SNCA (0.50) | SNCAMAPTKMT2AMEN1NOX1 | |
| SCHEMBL10590538 | 0.70 | MEN1 (0.40) | SNCAMAPTKMT2AMEN1NOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4859667-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1989-08-22 | — | — | US | claimed |
| EP-0247723-A2 | Compositions and methods for treating allergic conjuctivitis | MERCK FROSST CANADA INC. (CA) | 1987-12-02 | — | — | EP | claimed |
| EP-0155623-A2 | Use of lipoxygenase inhibitors for the preparations of cytoprotective pharmaceutical compostions and process for the preparation of a cytoprotective pharmaceutical composition | MERCK & CO. INC. (US) | 1985-09-25 | — | — | EP | claimed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| WO-2014176460-A1 | METHODS OF TREATING BEHAVIORIAL AND/OR MENTAL DISORDERS | CHAU DAVID T (US) | 2014-10-30 | — | — | WO | disclosed |
| US-8486922-B2 | Composition | CHEN CHIEN-HUNG (TW) | 2013-07-16 | — | — | US | disclosed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | disclosed |
| US-7790723-B2 | Thiazole derivatives as phosphodiesterase IV inhibitors | MERCK PATENT GMBH (DE) | 2010-09-07 | — | — | US | disclosed |
| EP-1343769-B1 | BENZOYLPYRIDAZINES | MERCK PATENT GMBH (DE) | 2010-08-04 | — | — | EP | disclosed |
| EP-1511737-B1 | ARYLOXIMES | MERCK PATENT GMBH (DE) | 2010-02-17 | — | — | EP | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| WO-2002051814-A1 | BENZOYLPYRIDAZINES | MERCK PATENT GMBH (DE) | 2002-07-04 | — | — | WO | disclosed |
| WO-2001057036-A1 | NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | disclosed |
| EP-0138481-B1 | LEUKOTRIENE BIOSYNTHESIS INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1991-06-26 | — | — | EP | disclosed |
| US-4845083-A | PHENOTHIAZINE DERIVATIVES AND ANALOGS | MERCK FROSST CANADA, INC. (CA) | 1989-07-04 | — | — | US | disclosed |
| EP-0115394-B1 | PHENOTHIAZONE DERIVATIVES AND ANALOGS | MERCK FROSST CANADA INC. (CA) | 1989-06-28 | — | — | EP | disclosed |
| EP-0247723-A2 | Compositions and methods for treating allergic conjuctivitis | MERCK FROSST CANADA INC. (CA) | 1987-12-02 | — | — | EP | disclosed |
| EP-0155623-A2 | Use of lipoxygenase inhibitors for the preparations of cytoprotective pharmaceutical compostions and process for the preparation of a cytoprotective pharmaceutical composition | MERCK & CO. INC. (US) | 1985-09-25 | — | — | EP | disclosed |
| EP-0138481-A2 | Leukotriene biosynthesis inhibitors | MERCK FROSST CANADA INC. (CA) | 1985-04-24 | — | — | EP | disclosed |
| EP-0115394-A2 | Phenothiazone derivatives and analogs | MERCK FROSST CANADA INC. (CA) | 1984-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | SNCA 4063/4885MAPT 2546/4885KMT2A 2361/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | SNCA 4063/4885MAPT 2546/4885KMT2A 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.